The British Journal of Psychiatry
February 1, 2025
Allan H. Young, Pierre-Michel Llorca, Andrea Fagiolini et al.
7 citations
In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release. To determine the robustness of the ESCAPE-TRD results and confirm the superiority of esketamine nasal spray over quetiapine extended release. ESCAPE-TRD was a randomised, open-label, rater-blinded, active-controlled phase IIIb trial. Patients had...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 31, 2025
Júnia L. de Deus, Juliana Marino Maia, Renato Nery Soriano et al.
27 citations
Neuroinflammation is a critical factor in the pathogenesis of various neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and major depressive disorder. Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), have demonstrated promising therapeutic effects on neuroinflammation, primarily through interactions...
Scientific Reports
January 29, 2025
Richard J. Zeifman, Meg J. Spriggs, Hannes Kettner et al.
26 citations
The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs. We conducted a preliminary examination of two psychological assumptions of REBUS: (a) psychedelics foster acute relaxation and post-acute revision of confidence in mental-health-relevant beliefs; which (b) facilitate positive...
January 22, 2025
Vito F. Palmisano
Research into new treatments for neuropsychiatric disorders has progressed slowly over the past 50 years, with limited breakthroughs. However, the psychedelic renaissance is opening promising new avenues for therapy, offering the potential to reduce side effects and eliminate the need for chronic use of traditional antidepressants. A key goal in neuropharmacology today is to understand the role...
bioRxiv Preprint Server
January 22, 2025
Emma R. Huels, Nicholas Kolbman, Christopher W Fields et al.
4 citations
preprint
Serotonergic psychedelics enhance neurophysiological complexity and the repertoire of brain states, whereas general anesthetics produce opposite effects. Serotonergic psychedelics are also known to increase wakefulness and reduce sleep time in rodents. Therefore, we hypothesized that 2,5-dimethoxy-4-iodopamphetamine (DOI), a serotonergic psychedelic, will reverse general anesthesia and restore...
Psychedelic Medicine
January 20, 2025
Marianna Graziosi, Gabrielle Agin-Liebes, Mary P Cosimano et al.
9 citations
Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for...
bioRxiv : the preprint server for biology
January 16, 2025
Yungyi Hsiao, Marcos As Fonseca, Alina S Tiemroth et al.
preprint
Psychedelics engage the serotonergic system as potent neuromodulators, increasing neuroplasticity in humans and rodents. Persistent changes in cognitive flexibility, emotional regulation, and social cognition are thought to underlie the therapeutic effects of psychedelics. However, the underlying molecular and cellular basis of psychedelic-induced plasticity remains unclear. Here, we identify...
Current Pain and Headache Reports
January 16, 2025
Isabella Henderson, Ronnie Elsaadany, Gabriel Chan et al.
4 citations
Exploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This review addresses the need for well-informed physician guidelines and discusses mechanisms, safety, and efficacy of these treatments. Further research, including the consideration of combination with psychotherapy, is needed. Psychedelics demonstrate...
Journal of Education, Health and Sport
January 14, 2025
Wiktoria Podlasiewicz, Paweł Siudziński, Mateusz Łyko et al.
MDMA or 3,4- methylenedioxymethamphetamine is a psychoactive substance, exhibiting mild hallucinogenic properties, that became widely known as a recreational party drug. However, its ability in helping individuals access deeply rooted emotions has prompted significant interest in its potential applications within clinical practice. MDMA’s mechanism of action involves increasing the release of...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 10, 2025
Randall D Ordovich-Clarkson, Maurice Jabbour, Daniel Arteaga Pelayo et al.
7 citations
Treatment of Parkinson's disease (PD) has remained largely unchanged and focuses primarily on symptomatic relief through activation of dopaminergic pathways. Currently, there are no proven prophylactic approaches to the prevention of PD. This systematic review seeks to compare two separate compounds, metformin (MTF) and psilocybin, as potential prophylactic therapeutics against the development...